17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Extramedullary myeloid sarcoma (MS, also known as granulocytic sarcoma, myeloblastoma or chloroma) is a rare form (<1%) of extramedullary acute myeloid leukemia (AML) presenting without bone marrow involvement. 1 Due to the rarity of this disease, contemporary clinical data are mostly limited to small case series. 2, 3, 4, 5 The prognostic factors and outcomes of extramedullary MS are unclear. Similar to AML, the current National Comprehensive Cancer Network guidelines recommend initial treatment with induction chemotherapy for all patients diagnosed with extramedullary MS. 6 In this study, we utilized the National Cancer Database (NCDB) to describe the clinical features, prognostic factors and early treatment outcomes in extramedullary MS. We identified patients with a histologically confirmed diagnosis of extramedullary MS from 2004 to 2013 using International Classification of Diseases for Oncology version 3 (ICD-O-3) code 9930 from the NCDB. The NCDB is a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society that collects outcomes data for over 1500 Commission-accredited cancer programs in the nation, and accounts for >70% of new cancer diagnoses. 7 Primary site codes were used to group extramedullary MS patients by location. We excluded patients whose primary site code was bone marrow. We analyzed overall survival (OS) using Kaplan–Meier estimates and their differences between race and sex using log-rank tests. To allow for ⩾1 year of follow-up, we excluded patients diagnosed in 2013 from OS analysis. To ascertain accuracy of follow-up, the OS analysis also excluded patients whose treatment decisions were made at a facility outside of the reporting facility. Multivariate analysis was performed adjusting for age, sex, race and disease location. Because NCDB records only the initial treatment and not subsequent therapies, we performed a landmark OS analysis among those patients who survived ⩾1 month according to treatments received during the first month after diagnosis. We investigated the effect of early chemotherapy, surgery and radiation on survival using Cox regression models. This analysis was done separately for patients older and younger than 70-years of age. A total of 94 185 cases of AML were reported from 2004 to 2013. During this time period, there were 746 patients diagnosed with extramedullary MS and comprised 0.8% of all AML diagnoses. The median age was 59 years (range, 41–73), and 56.1% were male. The distribution by race was 80.2% White, 9.1% Black, 2.9% Asian, and 7.8% others/unknown. Primary site was divided into 11 categories based on organ involved at presentation of extramedullary MS (Table 1). The three most common sites of presentation were connective/soft tissues (31.3%), skin/breast (12.3%) and digestive system (10.3%). The median OS for the entire cohort was 12.8 months. According to OS, we categorized the patients into three prognostic groups: good (OS >30 months: reproductive and digestive systems), intermediate (OS 15–30 months: head/neck, skin/breast and kidney/bladder/retroperitoneum/adrenal) and poor (OS <15 months: nervous system, connective/soft tissue, lymph nodes/spleen, cardiac/mediastinal and bones/joints). Compared to other races, Blacks were more likely to have extramedullary MS involving lymph nodes/spleen (4.4 vs 13.1%, P=0.03). Asians were more likely to have cardiopulmonary/mediastinal disease as compared to other races (13.6 vs 4.0%, P=0.02). Although both age groups had a similar proportion of poor prognosis sites (60.0%), younger (<70 years) patients were more likely to have good prognosis sites as compared to older patients (⩾70 years; 19.0 vs 10.9%, P=0.005). On multivariate analysis, factors affecting OS were age (P<0.0001), sex (P=0.0195), race (P=0.0009), as well as disease location (P=0.0027). Median OS was worse among males (HR 1.26; 95% CI 1.03–1.54), elderly (HR 2.42; 1.97–2.97), Blacks (HR 1.66; 95% CI 1.22–2.23) and those involving poor prognosis sites (HR 1.44; 95% CI 1.03–2.06) as compared to their counterparts. We included 533 patients in the landmark analysis based on early treatment. Chemotherapy was administered to 37.7% of the patients, while 25.3% had surgery or radiation therapy only. The remaining (37%) patients did not undergo any treatment within 30 days of diagnosis. A very small proportion of patients underwent a hematopoietic stem cell transplant (3.4%), although the exact nature of conditioning regimen and donor source was unavailable. Early chemotherapy had no effect on OS in younger patients (HR=0.93; 95% CI=0.68–1.28). Among older patients, receiving early chemotherapy was associated with higher mortality (HR=2.59; 95% CI=1.54–4.36) (Figures 1a and b). It is worthwhile to note that a substantial proportion (19.9%) of patients underwent chemotherapy after 30 days of diagnosis (Supplementary Figure S1). Of this latter group, 25% underwent surgery and 14% underwent radiation therapy before receiving systemic chemotherapy. However, analyzing OS at later landmarks (60 and 90 days) yielded similar results for survival between chemotherapy and no chemotherapy subgroups. Ours is the largest study of extramedullary MS in the United States. A previous study included 345 patients with extramedullary MS from the surveillance, epidemiology and end results (SEER) database from 1973 to 2010 and demonstrated superior median OS for extramedullary MS as compared to AML without MS (8 vs 5 months). 8 This study also showed improved survival for pelvic/genitourinary, gastrointestinal mucosa, gonads/eye as compared to nervous system, soft tissue and lymph node/hematopoietic tissue. In contrast, a study from Toronto evaluated 90 patients with extramedullary MS and did not find any correlation between the site of disease and outcomes. 9 The reason for the difference in OS among various disease sites is unclear. The initial treatment received was similar among the sites involved (Table 1). Reproductive and digestive system MS may have a better prognosis due to early symptom onset and detection, while poorer survival in bone MS may indicate early onset marrow involvement. Upon reviewing these findings, one may hypothesize that extramedullary MS involving the poor prognosis sites may benefit from early chemotherapy. Previous institutional studies have shown that the median time to develop AML from extramedullary MS ranged from 5 to 12 months. Hence most experts recommend treating extramedullary MS with induction chemotherapy. 10 A case series of 15 patients with extramedullary MS and 46 AML patients with MS showed that 87% (13/15) of extramedullary MS cases developed AML. 2 The entire cohort consisted of a higher proportion of poor prognosis sites (bone and lymph node) than ours. In a subsequent series of 16 patients with extramedullary MS, only 7 (44%) developed AML. 11 Six out of these seven patients died within 5 weeks to 16 months after diagnosis, despite systemic chemotherapy in five of those six patients. The disease sites for patients who progressed were nervous system (2), skin/subcutaneous tissue (2) and one each of uterine, ileal and nasal fossa. 11 It is to be noted that four of the nine patients who did not progress to AML (intermediate/good prognosis sites) were alive without evidence of disease at 3.5–16 years of initial presentation and had received systemic chemotherapy. 11 These findings, along with our study, suggest prognostic differences based on site of involvement of extramedullary MS, and median OS for some of the disease sites like reproductive and digestive system is perhaps better than AML in general. We showed a disparity in OS according to sex and race. As seen in prior studies of AML, Blacks had a worse survival as compared to Whites. 12 Both these differences in sex and race were not seen in prior MS series, likely due to smaller sample size. 8 The racial disparity in survival could be ascribed to higher frequency of the poor prognosis sites (lymph nodes/spleen) in Blacks as shown in our study, or due to disease heterogeneity. In our study, only 37% of the patients received systemic chemotherapy within the first 30 days. A similar proportion of patients did not receive any treatment during the same time period, with no difference in outcomes as compared to early systemic or local therapies in younger patients. Of note, NCDB does not contain information whether any of these patients received second line chemotherapy. Hence, our focus was on the role of early treatment. In our study, early systemic chemotherapy was associated with worse outcomes in older patients (>70 years) as compared to early radiation/surgery or no treatment. This may be explained by a lower frequency of good prognosis sites in older patients, thereby suffering from the combined impact of worse disease biology and chemotherapy-related toxicities. The primary limitations of our study are those related to its derivation from a database. It does not give us information about the patients who progressed to AML and the exact treatment regimens received. Nevertheless, it is the largest database for malignant diseases in the United States and is especially helpful in assessing prognosis in rare diseases like extramedullary MS, where traditional clinical studies are limited by sample size. Our study demonstrates that extramedullary MS has a diverse anatomic clinical presentation and the OS varied significantly according to age, sex, race and sites of presentation. Randomized trials analyzing optimal treatment strategy for extramedullary MS would be challenging to conduct due the rarity of the condition. Hence the results of our study may aid the prognostication of patients for treatment planning and in the understanding of the biological differences by anatomic sites of presentation.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

          Myeloid sarcoma (MS) is a rare neoplasm whose knowledge is largely based on case reports and/or technically dated contributions. Ninety-two MSs in adulthood with clinical data available were evaluated both morphologically and immunohistochemically. Seventy-four cases were also studied by fluorescent in situ hybridization on tissue sections and/or conventional karyotyping on bone marrow or peripheral blood. Histologically, 50% of the tumors were of the blastic type, 43.5% either monoblastic or myelomonocytic and 6.5% corresponded to different histotypes. CD68/KP1 was the most commonly expressed marker (100%), followed by myeloperoxidase (83.6%), CD117 (80.4%), CD99 (54.3%), CD68/PG-M1 (51%), CD34 (43.4%), terminal-deoxy-nucleotidyl-transferase (31.5%), CD56 (13%), CD61/linker for activation of T cells (2.2%), CD30 (2.2%) and CD4 (1.1%). Foci of plasmacytoid monocyte differentiation were observed in intestinal cases carrying inv16. Chromosomal aberrations were detected in about 54% of cases: monosomy 7(10.8%), trisomy 8(10.4%) and mixed lineage leukemia-splitting (8.5%) were the commonest abnormalities, whereas t(8;21) was rare (2.2%). The behavior was dramatic irrespective of presentation, age, sex, phenotype and cytogenetics. Most if not all, long survivors received bone-marrow transplantation. The present report expands the spectrum of our knowledge showing that MS has frequent monoblastic/myelomonocytic differentiation, displays distinctive phenotypic profile, carries chromosomal aberrations other than t(8;21), and requires supra-maximal therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            How I treat extramedullary acute myeloid leukemia.

            Extramedullary (EM) manifestations of acute leukemia include a wide variety of clinically significant phenomena that often pose therapeutic dilemmas. Myeloid sarcoma (MS) and leukemia cutis (LC) represent 2 well-known EM manifestations with a range of clinical presentations. MS (also known as granulocytic sarcoma or chloroma) is a rare EM tumor of immature myeloid cells. LC specifically refers to the infiltration of the epidermis, dermis, or subcutis by neoplastic leukocytes (leukemia cells), resulting in clinically identifiable cutaneous lesions. The molecular mechanisms underlying EM involvement are not well defined, but recent immunophenotyping, cytogenetic, and molecular analysis are beginning to provide some understanding. Certain cytogenetic abnormalities are associated with increased risk of EM involvement, potentially through altering tissue-homing pathways. The prognostic significance of EM involvement is not fully understood. Therefore, it has been difficult to define the optimal treatment of patients with MS or LC. The timing of EM development at presentation versus relapse, involvement of the marrow, and AML risk classification help to determine our approach to treatment of EM disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases.

              Granulocytic sarcoma is an uncommon tumor composed of granulocytic precursor cells. Because it occurs in a variety of clinical settings and because the tumor cells are primitive it is frequently unrecognized during life. This presentation details the authors' experience with 61 biopsy-proven granulocytic sarcomas. The patient age range was from 2 to 81 years (mean 48 years). In eight patients the tumors were multiple. Most common sites of involvement were bone, periosteum, soft tissue, lymph node and skin. Twenty-two tumors occurred in 15 patients with no known disease, 26 occurred in 24 patients with a known myeloproliferative disorder, and 13 occurred in 11 patients with proven acute myeloid leukemia. Thirteen of the 15 patients with no known disease developed acute leukemia in from one to 49 months after the biopsy of their tumors (mean 10 months). Most tumors occurring in patients with a known myeloproliferative disorder were associated with blast crisis. The authors' cases displayed a morphologic range from well-differentiated to those tumors that displayed virtually no evidence of differentiation by conventional microscopy. It was therefore not surprising that most tumors were originally diagnosed as lymphoma. Chloro-acetate esterase (CAE) stains were performed on 56 tumors and 47 were studied with antilysozyme immunoperoxidase technique. Fifty-six of the 57 specimens studied by either technique were positive. Antilysozyme immunoperoxidase stains were particularly useful in confirming the diagnosis.
                Bookmark

                Author and article information

                Journal
                Blood Cancer J
                Blood Cancer J
                Blood Cancer Journal
                Nature Publishing Group
                2044-5385
                August 2017
                25 August 2017
                1 August 2017
                : 7
                : 8
                : e592
                Affiliations
                [1 ]Division of Hematology, Mayo Clinic , Rochester, MN 55905, USA
                [2 ]Division of Biomedical Statistics and Informatics, Mayo Clinic , Rochester, MN 55905, USA
                Author notes
                Article
                bcj201779
                10.1038/bcj.2017.79
                5596389
                28841208
                3141e1bb-5fc8-40cc-b0b5-5b13c470dfb2
                Copyright © 2017 The Author(s)

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                Categories
                Letter to the Editor

                Oncology & Radiotherapy
                Oncology & Radiotherapy

                Comments

                Comment on this article